Becton Dickinson stock (US0718131099): Medical device maker reports latest results and outlook for 2

Becton Dickinson has released its latest quarterly results, reporting approximately $4.7 billion in revenue and adjusted earnings per share of $2.10 for the quarter ended March 31, 2026. The company reiterated its full fiscal year 2026 revenue guidance with mid-single-digit growth and low to mid-single-digit adjusted EPS growth, driven by innovation in drug delivery and digital health solutions. Becton Dickinson continues to balance operational challenges with long-term growth by leveraging its diversified portfolio in medical devices, diagnostics, and life sciences.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin